Sun Pharma gets Australian regulatory nod for acne vulgaris treatment Winlevi

Although the exact mechanism of action for Winlevi is unknown, laboratory studies suggest the active ingredient, clascoterone, competes with androgens, specifically dihydrotestosterone (DHT), for binding to the androgen receptors within the sebaceous gland and hair follicles. Androgens are widely recognized as the most important of all hormones in terms of regulating sebum production. Within the skin, androgens bind to androgen receptors, causing increased sebum production and inflammation. In particular, the skin of patients with acne vulgaris produces higher levels of the androgens testosterone and dihydrotestosterone (DHT) than the skin of healthy individuals. Winlevi binds to the androgen receptor competing with androgens such as DHT on cells within the sebaceous gland. Although its precise mechanism of action is unknown, studies suggest Winlevi inhibits androgen receptors in the skin and reduces production of sebum and inflammation. Additionally, Winlevi is rapidly metabolized in the skin, limiting systemic absorption.

Sun Pharma has received from Cosmo the exclusive right to develop and commercialize WINLEVI in US, Japan, Australia, New Zealand, Brazil, Mexico and Russia.

Sun Pharma is a specialty generics company with presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a generic company in the US as well as Global Emerging Markets. Sun’s high growth Global Specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatology and accounts for over 16% of company sales. Its manufacturing facilities are spread across six continents. 

Read also: Sun Pharma topical acne treatment Winlevi now available in Canada